STOCK TITAN

Axogen, Inc. to Report First Quarter Financial Results and Host Conference Call on May 5, 2021

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

Axogen, Inc. (NASDAQ: AXGN) will announce its first quarter 2021 financial results on May 5, 2021, after market close. The company's management will host a conference call and webcast at 4:30 p.m. ET to discuss the results. Interested investors can participate via phone or listen live on Axogen's website. The company focuses on developing innovative surgical solutions for peripheral nerve repair, including products like Avance® Nerve Graft and Axoguard Nerve Connector®. These offerings aim to restore nerve function and improve patient quality of life.

Positive
  • Upcoming financial results expected to show growth and development.
  • Innovative product portfolio targeting peripheral nerve repair.
Negative
  • None.

ALACHUA Fla. and TAMPA, Fla., April 14, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that it will report first quarter 2021 financial results on Wednesday, May 5, 2021 after the market closes. Axogen management will host an investment-community conference call and webcast following the release at 4:30 p.m. ET.

Investors interested in participating in the conference call by phone may do so by dialing toll free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. Those interested in listening to the conference call live via the Internet may do so by visiting the Investors page of the company's website at www.axogeninc.com and clicking on the webcast link.

Following the conference call, a replay will be available in the Investors section of the company's website at www.axogeninc.com.

About Axogen
Axogen (AXGN) is the leading company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about helping to restore peripheral nerve function and quality of life to patients with physical damage or transection to peripheral nerves by providing innovative, clinically proven, and economically effective repair solutions for surgeons and health care providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve, or the inability to properly reconnect peripheral nerves, can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain.

Axogen's platform for peripheral nerve repair features a comprehensive portfolio of products, including Avance® Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; Axoguard Nerve Connector®, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; Axoguard Nerve Protector®, a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments; Axoguard Nerve Cap®, a porcine submucosa ECM product used to protect a peripheral nerve end and separate the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive® Soft Tissue Membrane, a processed human umbilical cord intended for surgical use as a resorbable soft tissue barrier. The Axogen portfolio of products is available in the United States, Canada, the United Kingdom, South Korea, and several other European and international countries.

Contact:
Axogen, Inc.
Peter Mariani, Executive Vice President and Chief Financial Officer
InvestorRelations@axogeninc.com


FAQ

When will Axogen release its first quarter 2021 financial results?

Axogen will report its first quarter 2021 financial results on May 5, 2021, after market close.

What time is the Axogen conference call scheduled?

The conference call is scheduled for 4:30 p.m. ET on May 5, 2021.

How can I participate in Axogen's conference call?

Investors can participate in the conference call by dialing 877-407-0993 or 201-689-8795, or listen live on the company's website.

What products does Axogen offer for nerve repair?

Axogen's product portfolio includes Avance® Nerve Graft and Axoguard Nerve Connector®, among others.

Where can I find a replay of Axogen's conference call?

A replay of the conference call will be available in the Investors section of Axogen's website following the event.

Axogen, Inc.

NASDAQ:AXGN

AXGN Rankings

AXGN Latest News

AXGN Stock Data

587.95M
41.56M
5.55%
84.61%
2.57%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States of America
ALACHUA